GlassScriptPhysician profile
Erin Marc Moore
NPI 1033119037
$300,034.76
in general payments reported to CMS, 2019-2025
38 companies · $34K in 2025
The $34K reported for 2025 was more than what 96% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $58K · 2021: $24K · 2022: $41K · 2023: $20K · 2024: $54K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $84K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Travel and Lodging: $7,035 · Food and Beverage: $5,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $84,362.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,575.00 |
| Travel and Lodging | $7,034.94 |
| Food and Beverage | $5,786.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $145,428.30 | 2019-2025 | Azur Cx Detachable, Glidewire, Glidesheath Slender |
| W. L. Gore & Associates, INC. | $62,625.34 | 2019-2025 | Excluder Conformable Aaa Endoprosthesis With Active Control, Gore Excluder Iliac Branch Endoprosthesis, Gore Excluder Thoracoabdominal Branch Endoprosthesis |
| Cvrx, INC. | $26,675.58 | 2021-2025 | Barostim Neo System |
| Medtronic, INC. | $21,250.10 | 2021-2025 | Hawkone, Turbohawk, Endurant Iis |
| Abbott Laboratories | $12,645.23 | 2019-2023 | Amplatzer, Diamondback Peripheral, Jeti |
| Medtronic Vascular, INC. | $10,391.84 | 2019-2020 | |
| Endologix LLC | $6,955.43 | 2019-2025 | Alto Abdominal Stent Graft System, Endocross Device, Torus Stent Graft System |
| Centerline Biomedical INC. | $5,116.74 | 2021-2022 | |
| Ge Healthcare | $1,853.38 | 2021-2023 | |
| Silk Road Medical, INC. | $1,681.33 | 2019-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Siemens Medical Solutions USA, INC. | $1,203.52 | 2020-2021 | |
| Bolton Medical INC | $838.46 | 2024-2025 | Treo Abdominal Stent-Graft System |
| Bard Peripheral Vascular, INC. | $743.25 | 2019-2021 | |
| Boston Scientific Corporation | $709.63 | 2019-2024 | Ranger, Eluvia |
| Venclose INC. | $224.98 | 2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$625,018.40 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.